We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Takeda Announces Mutual Termination of Amylin/Takeda Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
Takeda Announces Mutual Termination of Amylin/Takeda Worldwide Agreement to Co-Develop and Commercialize Compounds for Obesity
December 26, 2012
Takeda Pharmaceutical Company announced that it has mutually terminated its worldwide agreement with Amylin Pharmaceuticals, originally signed in October 2009, to co-develop and commercialize compounds for obesity. Yahoo! Finance
